

Lanreotide

Chemical Properties

CAS No. : 108736-35-2


Formula: C₅₄H₆₉N₁₁O₁₀S₂

Molecular Weight: 1096.32

Keep away from moisture

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Lanreotide, a somatostatin analogue, suppresses GH/IGF-I hypersecretion in acromegaly patients. It also used to manage neuroendocrine tumours.
Targets(IC50)	Somatostatin

Solubility Information

Solubility	DMSO: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.9121 mL	4.5607 mL	9.1214 mL
5 mM	0.1824 mL	0.9121 mL	1.8243 mL
10 mM	0.0912 mL	0.4561 mL	0.9121 mL
50 mM	0.0182 mL	0.0912 mL	0.1824 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langle A, Martinez S, Blumberg J, Ruzniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med*. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. PubMed PMID: 25014687.

Burness CB, Dhillon S, Keam SJ. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly. *Drugs*. 2014 Sep;74(14):1673-91. doi: 10.1007/s40265-014-0283-8. Review. PubMed PMID: 25193626.

Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. *BMC Cancer*. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6. PubMed PMID: 26138480; PubMed Central PMCID: PMC4490650.

Zheng N, Dai W, Zhang H, Wang X, Wang J, Zhang X, Wang K, Li J, Zhang Q. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. *J Drug Target*. 2015 Jan;23(1):67-78. doi: 10.3109/1061186X.2014.954118. Epub 2014 Nov 4. PubMed PMID: 25366085.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481